508 related articles for article (PubMed ID: 27045254)
1. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Hatzimouratidis K; Salonia A; Adaikan G; Buvat J; Carrier S; El-Meliegy A; McCullough A; Torres LO; Khera M
J Sex Med; 2016 Apr; 13(4):465-88. PubMed ID: 27045254
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for erectile dysfunction.
Eardley I; Donatucci C; Corbin J; El-Meliegy A; Hatzimouratidis K; McVary K; Munarriz R; Lee SW
J Sex Med; 2010 Jan; 7(1 Pt 2):524-40. PubMed ID: 20092451
[TBL] [Abstract][Full Text] [Related]
3. Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Salonia A; Adaikan G; Buvat J; Carrier S; El-Meliegy A; Hatzimouratidis K; McCullough A; Morgentaler A; Torres LO; Khera M
J Sex Med; 2017 Mar; 14(3):297-315. PubMed ID: 28262100
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil.
Moncada I; Martinez-Salamanca J; Ruiz-Castañe E; Romero J
Int J Impot Res; 2018 Oct; 30(5):203-208. PubMed ID: 30050072
[TBL] [Abstract][Full Text] [Related]
5. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
6. Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Salonia A; Adaikan G; Buvat J; Carrier S; El-Meliegy A; Hatzimouratidis K; McCullough A; Morgentaler A; Torres LO; Khera M
J Sex Med; 2017 Mar; 14(3):285-296. PubMed ID: 28262099
[TBL] [Abstract][Full Text] [Related]
7. Alprostadil for the treatment of impotence.
Hanchanale V; Eardley I
Expert Opin Pharmacother; 2014 Feb; 15(3):421-8. PubMed ID: 24369066
[TBL] [Abstract][Full Text] [Related]
8. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.
Hedelin H; Ströberg P
Drugs; 2005; 65(16):2245-51. PubMed ID: 16266193
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
[TBL] [Abstract][Full Text] [Related]
10. Intraurethral alprostadil for erectile dysfunction: a review of the literature.
Costa P; Potempa AJ
Drugs; 2012 Dec; 72(17):2243-54. PubMed ID: 23170913
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
Garrido Abad P; Sinués Ojas B; Martínez Blázquez L; Conde Caturla P; Fernández Arjona M
Actas Urol Esp; 2015 Dec; 39(10):635-40. PubMed ID: 26049734
[TBL] [Abstract][Full Text] [Related]
12. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Hatzimouratidis K; Hatzichristou DG
Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
[TBL] [Abstract][Full Text] [Related]
13. An update on the drug safety of treating erectile dysfunction.
Gul M; Serefoglu EC
Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
[No Abstract] [Full Text] [Related]
14. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
[TBL] [Abstract][Full Text] [Related]
15. Current role of local treatments for erectile dysfunction in the real-life setting.
Moisidis K; Kalinderis N; Hatzimouratidis K
Curr Opin Urol; 2016 Mar; 26(2):123-8. PubMed ID: 26716564
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Lee M; Sharifi R
Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
19. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
[TBL] [Abstract][Full Text] [Related]
20. Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury.
Bodner DR; Haas CA; Krueger B; Seftel AD
Urology; 1999 Jan; 53(1):199-202. PubMed ID: 9886612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
